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The efficacy of bacterial vaccines to prevent respiratory diseases in swine: A
protocol for a systematic review
Abstract
The treatment and prevention of infectious diseases in pigs is an important aspect of swine production
worldwide. The prudent use of antimicrobials and other therapeutic drugs is a primary responsibility of swine
producers and veterinarians and decisions surrounding the use of drug therapy include considerations such as
cost, efficacy, and food safety. The World Health Organization has published numerous reports urging all
stakeholders concerned with both food-producing animals and humans to establish recommended steps to
enhance the prudent use of antimicrobials (WHO, 2015). Similarly, the Organization for Animal Health has
also published recommendations and position statements regarding prudent use and risk management related
to antimicrobial use in animals (OIE, 2017).
Antibiotic therapy is used to treat and prevent respiratory diseases in pigs and there are numerous pathogenic
organisms involved in all of the predominant swine respiratory diseases (Karriker, et al, 2012). In addition to
antibiotics, vaccines targeted towards respiratory pathogens have been used extensively in swine production
and are often used in combination with other approaches to reduce the incidence of disease. The usefulness of
a vaccine or vaccine program varies from herd to herd and the complex interactions between host, agent and
environment in swine production makes the design of a vaccine program challenging for veterinarians. There
are many studies that have assessed the efficacy of antibiotics and vaccines for the treatment and prevention
Mycoplasma hyopneumonia, for example, however, they often report conflicting results adding to the
complexity of the decision-making process (Thacker and Minion, 2012).
Understanding the efficacy of these vaccines products is essential to optimizing their use in order to decrease
reliance on antibiotics for both treatment and prevention of swine respiratory disease. Systematic reviews of
randomized controlled trials in these areas will yield the highest level of evidence for efficacy of treatment
under field conditions (Sargeant and O’Connor, 2014). Although vaccines exist for both viral and bacterial
causes of respiratory diseases of swine, and antibiotics often are used in the treatment of both, this review will
focus on bacterial causes for logistical reasons.
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described	in	this	proposal.	JMS	drafted	the	protocol,	with	input	and	final	approval	of	all	co-
authors.	
	
Registration:		
This	protocol	is	archived	in	the	University	of	Guelph’s	institutional	repository	(The	Atrium;	
https://atrium.lib.uoguelph.ca/xmlui/handle/10214/10046)	and	published	online	with	
Systematic	Reviews	for	Animals	and	Food	(SYREAF)	available	at:		http://www.syreaf.org/.	The	
systematic	review	will	be	reported	using	the	Preferred	Reporting	Items	for	Systematic	Reviews	
and	Meta-Analyses	(PRISMA)	statement	guidelines	(Liberati	et	al.,	2009).		This	protocol	is	
reporting	using	the	items	(headings)	recommended	in	the	PRISMA-P	guidelines	(Moher	et	al.,	
2015).	
	
Support.		Funding	support	for	this	systematic	review	/	meta-analysis	/	network	meta-analysis,	
including	the	development	of	the	protocol,	was	provided	by	The	Pew	Charitable	Trusts.	
	
Introduction.	
	
Rationale:		
	
The	treatment	and	prevention	of	infectious	diseases	in	pigs	is	an	important	aspect	of	swine	
production	worldwide.		The	prudent	use	of	antimicrobials	and	other	therapeutic	drugs	is	a	
primary	responsibility	of	swine	producers	and	veterinarians	and	decisions	surrounding	the	use	
of	drug	therapy	include	considerations	such	as	cost,	efficacy,	and	food	safety.	The	World	Health	
Organization	has	published	numerous	reports	urging	all	stakeholders	concerned	with	both	
food-producing	animals	and	humans	to	establish	recommended	steps	to	enhance	the	prudent	
use	of	antimicrobials	(WHO,	2015).		Similarly,	the	Organization	for	Animal	Health	has	also	
published	recommendations	and	position	statements	regarding	prudent	use	and	risk	
management	related	to	antimicrobial	use	in	animals	(OIE,	2017).			
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Antibiotic	therapy	is	used	to	treat	and	prevent	respiratory	diseases	in	pigs	and	there	are	
numerous	pathogenic	organisms	involved	in	all	of	the	predominant	swine	respiratory	diseases	
(Karriker,	et	al,	2012).			In	addition	to	antibiotics,	vaccines	targeted	towards	respiratory	
pathogens	have	been	used	extensively	in	swine	production	and	are	often	used	in	combination	
with	other	approaches	to	reduce	the	incidence	of	disease.		The	usefulness	of	a	vaccine	or	
vaccine	program	varies	from	herd	to	herd	and	the	complex	interactions	between	host,	agent	
and	environment	in	swine	production	makes	the	design	of	a	vaccine	program	challenging	for	
veterinarians.		There	are	many	studies	that	have	assessed	the	efficacy	of	antibiotics	and	
vaccines	for	the	treatment	and	prevention	Mycoplasma	hyopneumonia,	for	example,	however,	
they	often	report	conflicting	results	adding	to	the	complexity	of	the	decision-making	process	
(Thacker	and	Minion,	2012).			
	
Understanding	the	efficacy	of	these	vaccines	products	is	essential	to	optimizing	their	use	in	
order	to	decrease	reliance	on	antibiotics	for	both	treatment	and	prevention	of	swine	
respiratory	disease.	Systematic	reviews	of	randomized	controlled	trials	in	these	areas	will	yield	
the	highest	level	of	evidence	for	efficacy	of	treatment	under	field	conditions	(Sargeant	and	
O’Connor,	2014).		Although	vaccines	exist	for	both	viral	and	bacterial	causes	of	respiratory	
diseases	of	swine,	and	antibiotics	often	are	used	in	the	treatment	of	both,	this	review	will	focus	
on	bacterial	causes	for	logistical	reasons.	
	
Objectives:		The	objective	of	this	protocol	is	to	describe	the	methods	for	a	systematic	review	–	
network	meta-analyses	to	address	the	efficacy	of	bacterial	vaccines	to	prevent	respiratory	
disease	in	swine.	 
			The	specific	PICO	elements,	which	will	define	the	eligibility	criteria,	are	as	follows:	
i. Population:	Live	swine	at	any	stage	of	production.		
ii. Intervention:	Vaccines	(commercially	available	or	commercially	produced	injectable	
autogenous	vaccines	derived	from	culture)	for	bacterial	pathogens	associated	with	
respiratory	diseases	in	swine,	including	Mycoplasma	hyopneumoniae,	Actinobacillus	
pleuropneumoniae,	Actinobacillus	suis,	Bordetella	bronchiseptica,	Pasteurella	multocida,	
Streptococcus	suis,	Haemophilus	parasuis	and		Mycoplasma	hyorhinis.	
iii. Comparator:		Negative	control	group	or	sham	treatment.		
iv. Outcomes:		The	outcomes	of	interest	are	respiratory-related	morbidity	(as	defined	by	the	
authors),	mortality,	and	total	antibiotic	use.	
	
Methods	
	
Eligibility	criteria:		In	addition	to	eligibility	criteria	inherent	in	the	PICO	elements	described	
above,	eligibility	includes	publication	in	English.		Both	journal	articles	and	other	forms	of	
research	reports	are	eligible,	provided	they	report	the	results	of	a	primary	research	study	with	a	
concurrent	comparison	group	using	an	eligible	study	design	and	a	full	text	of	more	than	500	
words.			
	
Study	designs	eligible:		Controlled	trials	with	natural	disease	exposure	will	be	eligible	for	
inclusion,	although	we	will	document	the	number	of	controlled	trials	with	deliberate	disease	
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challenge	and	analytical	observational	studies	at	full	text	screening	and	also	will	identify	the	
vaccines	used	and	whether	any	of	the	outcomes	of	interest	were	assessed	for	studies	of	these	
designs.		
	
Information	sources:			
	
We	will	conduct	the	literature	search	in	a	range	of	relevant	bibliographic	databases	and	other	
information	sources	containing	both	published	and	unpublished	literature.	Table	1	presents	the	
resources	to	be	searched.		
	
Table	1:		Databases	and	information	sources	to	be	searched	
	
Database	/	information	source	 Interface	/	URL	
MEDLINE	 PubMed	
CAB	Abstracts		 CAB	Interface	
Science	Citation	Index		 Web	of	Science	
Conference	 Proceedings	 Citation	 Index	 –	
Science	
Web	of	Science	
Agricola	 Proquest	
	
The	AASV	maintains	a	searchable	digital	library	of	proceedings	from	the	prominent	swine	
conferences	through	the	American	Association	of	Swine	Veterinarians	website	(Swine	
Information	Library	http://www.aasv.org/library/swineinfo/).	Selected	proceedings,	as	noted	
below,	will	be	search	using	the	key	words:	
(Vaccine	OR	vaccination)	AND		
(bacterial	OR	hyopneumoniae	OR	Mycoplasma	OR	Actinobacillus	OR	pleuropneumoniae	OR	
Actinobacillus	OR	“A.	suis”	OR	Bordetella		OR		bronchiseptica	OR		Pasteurella	OR	multocida	OR	
“Streptococcus	suis”	OR	“Strep.	suis”	OR	“S.	suis”	OR	Haemophilus	OR	parasuis	OR	hyorhinis)	
Resources	to	be	searched	on	this	site	include	proceedings	from:		
o	AASV	Annual	Meeting	(1999-2018)		
o	AASV	Pre-Conference	Seminars	(2007-2018)		
o	International	Pig	Veterinary	Society	Congress	(2000,	2002,	2004,	2006,	2008,	2010,	2012,	
2014,	2016,	2018)	
	
Search	strategy:			
	
A	Science	Citation	Index	(Web	of	Science)	search	strategy	designed	to	identify	studies	of	vaccine	
efficacy	for	bacterial	vaccines	for	respiratory	disease	in	swine	is	presented	in	Table	2.	The	
search	strategy	employs	a	multi-stranded	approach	to	maximize	sensitivity.		The	conceptual	
structure	is	as	follows:	
	
•	 Swine	at	any	stage	of	production;		
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AND	
•	 Vaccines;	
AND	
• Bacteria	associated	with	respiratory	disease	in	swine		
AND	
• Respiratory	outcomes	
	
	
Table	 2:	 Search	 strategy	 to	 identify	 studies	of	bacterial	 vaccines	 for	 respiratory	diseases	of	
swine	in	Science	Citation	Index	(Web	of	Science)	
	
#1				TS=	(swine	OR	pig*	OR	piglet*	OR	gilt*	OR	boar*	OR	sow*	OR	hog*	OR	weane*	OR	porcine	
NOT	guinea)		 	 877,032	 	
	
#2				TS	=	(vaccine	OR	vaccination	OR	bacterin)		 286,956	 	
	
#3				TS	=	(hyopneumoniae	OR	Mycoplasma	OR	Actinobacillus	OR	“atrophic	rhrinitis”	OR	suis	OR	
Bordetella	OR	bronchiseptica	OR		Pasteurella	OR	Pasteurellosis	OR	multocida	OR	Streptococcus	
OR	Haemophilus	OR	Glasser’s	OR	Glassers	OR	parasuis	OR	hyorhinis)	 159,419	 	 	
	
TS	=	(pneumonia	OR	pleuritis	OR	pleuropneumonia	OR	pleuropneumoniae	OR	respiratory	OR	
SRD)	 	 492,040	
	
#1	AND	#2	AND	#3	AND	#4	 	 743	
	
The	search	strategies	will	not	be	limited	by	date,	language,	or	publication	type.			
	
We	will	 conduct	 searches	using	each	database	 listed	 in	 the	protocol,	 translating	 the	 strategy	
appropriately	to	reflect	the	differences	in	database	interfaces	and	functionality.			
	
Study	records:	
	
			 Data	management:		We	will	download	the	results	of	searches	in	a	tagged	format	and	load	
them	into	bibliographic	software	(EndNote).	The	results	will	be	de-duplicated	using	several	
algorithms.		We	will	save	results	from	resources	that	do	not	allow	export	in	a	format	
compatible	with	EndNote	in	Word	or	Excel	documents	as	appropriate	and	manually	de-
duplicate.		The	de-duplicated	search	results	will	be	uploaded	into	online	systematic	review	
software	(DistillerSR®,	Ottawa,	ON,	Canada).	Reviewers	will	have	training	in	epidemiology	and	
in	systematic	review	methods.		Prior	to	both	abstract	and	full-text	screenings,	data	extraction,	
and	risk	of	bias	assessment,	the	reviewers	assigned	to	each	step	will	undergo	training	to	ensure	
consistent	data	collection	using	the	forms	created	in	DistillerSR®.		
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				Selection	process:			In	the	first	round	of	screening,	abstracts	and	titles	will	be	screened	for	
eligibility.	Two	reviewers	will	independently	evaluate	each	citation	for	relevance	using	the	
following	questions:	
1)	Does	the	study	evaluate	the	use	of	vaccines	for	bacterial	causes	of	respiratory	disease	in	live	
swine?		
YES	(neutral	response),	NO	(EXCLUDE),	UNCLEAR	(neutral	response)	
2) Is	there	a	concurrent	comparison	group?	(i.e.	controlled	trial	with	natural	or	deliberate	
disease	exposure	or	analytical	observational	study)?	
YES	(neutral	response),	NO	(EXCLUDE),	UNCLEAR	(neutral	response)	
3) Is	the	full	text	available	in	English?	
YES	(include	for	full	text	screening),	NO	(EXCLUDE),	UNCLEAR	(include	for	full	text	
screening)	
	
Citations	will	be	excluded	if	both	reviewers	responded	“no”	to	any	of	the	questions.		Any	
disagreements	will	be	resolved	by	consensus.		If	consensus	cannot	be	reached,	the	article	will	
be	marked	as	“unclear”	and	will	advance	to	full	text	screening.		A	pre-test	will	be	conducted	by	
all	reviewers	on	the	first	250	abstracts	to	ensure	clarify	of	questions	and	consistency	of	
understanding	of	the	questions.	
Following	title/abstract	screening,	eligibility	will	be	assessed	through	full-text	screening,	using	
the	questions	included	below.	Two	reviewers	will	independently	evaluate	the	full	text	articles,	
with	any	disagreements	resolved	by	consensus.	If	consensus	cannot	be	reached,	a	third	
reviewer	will	be	used.	A	pre-test	will	be	conducted	by	all	reviewers	on	the	first	10	full	texts	to	
ensure	clarify	of	questions	and	consistency	of	understanding	of	the	questions.	
1) Is	the	full	text	available	with	>	500	words?		
YES	(neutral	response),	NO	(EXCLUDE)	
2) Is	the	full	text	available	in	English?		
YES	(neutral	response),	NO	(EXCLUDE)	
3) Eligible	population:	Does	the	study	evaluate	live	swine?		
YES	(neutral	response),	NO	(EXCLUDE)	
4) Eligible	intervention:	Does	the	study	assess	the	use	of	a	monovalent	or	polyvalent	
commercially	available	vaccine	or	a	commercially	produced	injectable	autogenous	vaccine	
derived	from	culture)	for	one	or	more	of	the	following	bacterial	pathogens	associated	with	
respiratory	diseases	in	swine:	Mycoplasma	hyopneumoniae,	Actinobacillus	
pleuropneumoniae,	Actinobacillus	suis,	Bordetella	bronchiseptica,	Pasteurella	multocida,	
Streptococcus	suis,	Haemophilus	parasuis	or	Mycoplasma	hyorhinis.	
5) Are	at	least	one	of	the	following	outcomes	described:	respiratory	disease	related	
morbidity,	mortality,	antibiotic	use.	
YES	(neutral	response),	NO	(EXCLUDE)	
6) Is	there	a	concurrent	comparison	group?	(i.e.	controlled	trial	with	natural	or	deliberate	
disease	exposure	or	analytical	observational	study)?	
YES	(neutral	response),	NO	(EXCLUDE)	
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7) Eligible	study	design:	Is	the	study	a	controlled	trial	with	natural	disease	exposure?	
Yes	(moves	to	data	extraction	stage),	
No,	the	study	is	a	controlled	trial	with	deliberate	disease	induction	(indicate	the	
bacterial	vaccine(s)	used,	but	exclude	from	data	extraction)	
No,	the	study	is	an	observational	study	(indicate	the	bacterial	vaccine(s)	used	but	
exclude,	from	data	extraction)	
	
			Data	collection	process:		Data	will	be	extracted	by	two	reviewers	working	independently.		Any	
disagreements	will	be	resolved	by	consensus	or,	if	consensus	cannot	be	reached,	a	third	
reviewer	will	be	used.		Authors	will	not	be	contacted	to	request	missing	data	or	to	clarify	
published	results.		A	form	for	data	extraction	will	be	created	for	this	review	in	DistillerSR®	and	
pre-tested	on	4	full	text	articles	to	ensure	question	clarity.	
	
Data	items:		
	
Study	level	data	to	be	extracted	include:	
• Country	 where	 trial	 was	 conducted	 (if	 not	 stated,	 use	 country	 affiliation	 of	
corresponding	author)	
• Commercial	versus	research	trials	
• Number	of	herds	enrolled	in	study	
• Year(s)	the	study	was	conducted	
• Months	of	data	collection	
• Stage	of	production	for	allocation	of	the	vaccine	
• Stage(s)	of	production	where	the	outcome	was	measured	
• Reason	for	vaccinating:	endemic	disease,	prevention	of	clinical	disease,	in	response	to	a	
disease	outbreak,	not	reported	
	
Arm	level	data	collected:	
• Vaccine	name	as	reported	by	investigators	
• Target	bacteria	for	the	vaccine	
• Dose	/	route	/	frequency	of	administration	of	the	vaccine	
• Unit	of	allocation	of	the	vaccine	(individual,	pen)	
• Description	of	comparison	group	(no	treatment,	sham	vaccine)	
• Number	of	animals	enrolled	
• Number	of	pens	enrolled	
• Number	of	animals	/	pens	lost	to	follow	up	
• Number	of	animals	/	pens	analyzed	
• Any	additional	concurrent	treatments	given	to	the	intervention	groups.	
• The	 approach	 used	 in	 the	 analysis	 to	 account	 for	 non-independent	 observations	 (not	
applicable,	not	reported,	random	effects,	GEE,	other.	
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Outcomes	and	prioritization:			
	
• Respiratory-related	morbidity,	
• Mortality,	
• Total	antibiotic	use,	
	
These	outcomes	were	prioritized	based	on	their	impact	on	animal	health	and	welfare	and	their	
economic	importance.		Formal	evaluation	of	these	criteria	for	prioritization	was	not	
undertaken.	
	
The	specific	outcome	data,	as	described	below,	will	be	extracted	only	for	experimental	studies	
with	natural	disease	exposure.	
	
Outcome	data	to	be	collected:	
1) Respiratory-related	morbidity	
a. Case	definition	
b. Time	period	for	assessing	outcome,	frequency	of	outcome	assessment	
c. Level	at	which	outcome	data	were	measured	(animal	/	pen	/	herd)	
	
2) Mortality	
a. Level	at	which	outcome	data	were	measured	(animal	/	pen	/	herd)	
b. Time	period	for	assessing	outcome	
	
3) Total	antibiotic	use	
a. Measure	used	to	define	outcome	
b. Time	period	for	assessing	outcome	
c. Antibiotic(s)	used	
	
For	each	outcome,	we	will	extract	the	possible	metrics	in	the	following	order:		
• 1st	priority:	Adjusted	summary	effect	size	(adjusted	risk	ratio	or	adjusted	odds	ratio,	mean	
differences	for	continuous	outcomes)	and	variables	included	in	adjustment	and	
corresponding	precision	estimate		
• 2nd	priority:	Unadjusted	summary	effect	size				
• 3rd	priority:	Arm	level	risk	of	the	outcome,	or	arm	level	mean	of	the	outcome	
(continuous	outcomes)	
• Variance	components.	
	
Risk	of	bias	in	individual	studies:		Risk	of	bias	will	only	be	assessed	for	controlled	trials	with	
natural	disease	exposure.		Risk	of	bias	assessment	will	be	performed	at	the	outcome	level	for	
each	outcome	using	the	Cochrane	risk	of	bias	instrument	(Higgins	et	all,	2016),	with	the	
signaling	questions	modified	as	necessary	for	the	specific	review	question.	The	ROB-2.0	for	
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clustered	RCTs	and	individual	RCTs	will	be	used	depending	on	the	study	design	(Higgins	et	al.,	
2016).	These	tools	are	available	at	https://sites.google.com/site/riskofbiastool/welcome/rob-2-
0-tool.	
	
Data	synthesis:		
	
Network	meta-analysis.	Network	meta-analysis	(aka	mixed	treatment	comparison	meta-
analysis)	will	be	conducted	for	each	outcome,	and	separately	for	vaccines	for	each	of	the	
selected	bacterial	diseases.		Network	meta-analysis	will	use	the	approach	described	by	NICE	
Decision	Support	Unit	technical	document	(Dias	et	al.,	2014;	O’Connor	et	al.,	2013,	O’Connor	et	
al.,	2016).	The	approach	to	reporting	will	use	the	PRISMA-	NMA	(http://www.prisma-
statement.org/Extensions/NetworkMetaAnalysis.aspx).		Planned	a	priori	sub-group	analyses	
will	be	conducted	for	randomized	versus	non-randomized	trials.		
	
Meta-bias(es):		Small	study	effects	(“publication	bias”)	will	be	assessed	for	all	vaccines	where	
there	are	at	least	10	studies	in	the	meta-analysis.	If	feasible,	we	will	use	approaches	to	
assessing	publication	bias	in	the	network	of	evidence	using	previously	proposed	approaches	
(Mavridis	et	al.,	2013;	Mavridis	et	al.,	2014).		
	
Confidence	in	cumulative	evidence:		The	quality	of	evidence	for	each	outcome	will	be	assessed	
using	 the	 approach	 proposed	 by	 GRADE	 (GRADE,	 2015,	 Puhan	 et	 al.,	 2014),	 while	 also	
considering	the	nature	of	the	network	meta-analysis	 (Jansen	et	al.,	2011).	 	 If	 feasible,	we	will	
use	the	framework	from	the	CINeMA	platform	for	conveying	the	impact	of	risk	of	bias	on	the	
network	performance.				
	
Discussion:		
	
This	systematic	review	will	provide	a	synthesis	of	the	current	evidence	regarding	the	efficacy	of	
vaccines	to	prevent	bacterial	diseases	causing	respiratory	diseases	in	swine.		Results	will	be	
helpful	for	veterinarians	and	swine	producers	when	making	evidence-informed	decisions	
regarding	management	options	to	reduce	respiratory	illness	and	death	caused	based	bacteria,	
and	potentially	reduce	the	need	to	use	antibiotics	to	treat	respiratory	diseases.		The	results	also	
will	be	helpful	for	identifying	specific	gaps	in	knowledge	related	to	the	efficacy	of	these	vaccine	
for	targeting	additional	research.	
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